Discussion on the Monitoring Platform of Rational Use Management Indexes of Key Monitored Drugs of Medical Institutions in China
- VernacularTitle:我国医疗机构重点监控药品监测平台合理应用管理指标的探讨
- Author:
Di WANG
1
;
Xiangfeng WANG
2
;
Lichao MAO
2
;
Wei XIONG
3
;
Jing ZHAO
1
Author Information
1. National Center for Medical Service Administration，National Health Commission of the People’s Republic of China，Beijing 100810，China
2. Dept. of Pharmacy，the First Hospital of Jilin University，Changchun 130031，China
3. Dept. of Clinical Engineering and Information Technology，the First Affiliated Hospital，College of Medicine，Zhejiang University，Hangzhou 310003，China
- Publication Type:Journal Article
- Keywords:
Key monitored dr ugs;
Monitoring p latform;
Data acquisition;
Rational drug u se
- From:
China Pharmacy
2021;32(8):911-914
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE：To d iscuss the monitoring platform of rational use management indexes of key monitored drugs ，and to provide reference for improving their clinical application management. METHODS ：The method of literature research and expert demonstration was adopted ，the indexes of key monitored drugs in medical institutions were put forward. RESULTS & CONCLUSIONS：Finally，Eight general indexes as the list of top 20 drugs purchased by medical institutions ，the specifications of key monitored drugs purchased ，the utilization rate of key monitored drugs of inpatient ，the proportion of key monitored drugs revenue，the increase in the cost of key monitored drugs of inpatient ，the increase in the cost of key monitored drug of single inpatient，the increase of the cost per time of key monitored drugs of inpatient ，the proportion of doctor ’s order review for key monitored drugs were defined. Four major data acquisition projects as the general information of medical institutions ，medical record homepage ，inpatient medication data ，and medical institution drug procurement data were also defined. The monitoring platform of key monitored drugs in medical institutions can provide reference for improving the management of clinical application of key monitored drugs.
